Heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. One of the standard ways to treat clogged and damaged arteries currently is to implant vascular stents, which hold the vessels open and release such drugs as paclitaxel.
“Healthy arteries have elastic fibers that provide elasticity. They are like rubber bands in the tissue that allow expansion and recoil during blood flow,” Vyavahare said. “In most cardiovascular diseases, elastic fibers in arteries get damaged, creating hooks that can be used to target drugs.”
The nanoparticles, coated with a sticky protein, latch onto damaged arteries and can deliver a drug to the site in slow release fashion. These nanoparticles can be engineered to deliver an array of drugs to the damaged or clogged artery, a common example being paclitaxel, which inhibits cell division and helps prevent growth of scar tissue that can clog arteries. These particles also have unique surfaces that allow prolonged circulation time, providing more opportunities for these particles to accumulate at the damage site.
“We developed nanoparticles that have antibodies on the surface that attach to diseased sites like Velcro,” said Vyavahare. “Interestingly, these newly created nanoparticles only accumulate at the damaged artery, not in the healthy arteries, enabling site-specific drug delivery.”
“These nanoparticles can be delivered intravenously to target injured areas and can administer drugs over longer periods of time, thus avoiding repeated surgical interventions at the disease site,” said Aditi Sinha, a Clemson graduate student and lead author on a paper soon to be published in journal Nanomedicine: Nanotechnolgy, Biology and Medicine.
The work is a promising step toward new treatments for cardiovascular and other diseases. The research team is testing the nanoparticles to determine the most effective drug dosage for vascular tissue repair. This technology can have variety of applications in other diseases, such as chronic obstructive pulmonary disease, Marfan syndrome and elastic fiber-related disorders, such as aortic aneurysms.
Ranked No. 21 among national public universities, Clemson University is a major, land-grant, science- and engineering-oriented research university that maintains a strong commitment to teaching and student success. Clemson is an inclusive, student-centered community characterized by high academic standards, a culture of collaboration, school spirit and a competitive drive to excel.
This material is based upon work supported by the National Institutes of Health under grant nos. R01HL070969-08, R21HL084267 and P20GM103444 and Hunter Endowment at Clemson University. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Institutes of Health.